fda amgen - Search News

FDA, Amgen and Obesity

Bloomberg on MSN · 2d

Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs.

Hosted on MSN · 2d

Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold

Nearly 30 years after Matt Damon and Ben Affleck’s breakthrough movie, “Good Will Hunting,” they are sharing the screen again in the new Netflix film “RIP,” which is inspired by true events.

FierceBiotech · 2d

Amgen's early-stage obesity asset slapped with FDA hold

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial

2d

Amgen profits rise, next MariTide studies start by mid-year

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Pipeline Problems Mar Amgen’s Q4 Beat

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

With recent launches and more to come, Amgen's biosimilar business is trending up

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

21h

Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results